Amyris Reports Its Largest First-Half Operating Loss Since 2012
A growing balance of deferred cost of product revenue suggests business fundamentals might be significantly worse than reported.
Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring Today
A rumored merger has investors excited, although details are scarce.
What to Watch When Twist Bioscience Reports Fiscal Q3 Results
Can the company possibly live up to its lofty market valuation?
Renewable Energy Group Posts Surprise Q2 Profit
The biomass-based diesel manufacturer smashed through its own lowly expectations thanks to a boost from state and federal incentives.
Does the Hydrogen Economy Have a Pipeline Problem?
Manufacturing hydrogen from renewable energy sounds great, but there are significant limitations to transporting hydrogen fuels.
NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound
The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.
What to Watch When Albemarle Reports Q2 Earnings
The specialty chemicals manufacturer is expected to struggle in 2020, but it has undertaken significant efforts to preserve long-term business fundamentals.
What to Watch When Renewable Energy Group Reports
The renewable fuels manufacturer is contending with a historic slowdown in demand for transportation fuels. Are diesel fuels more insulated from uncertainty?
Repligen Reports Record Quarter, Increases 2020 Guidance
The coronavirus pandemic has done little to hamper the growth trajectory of the bioprocess engineering leader.
Here's Why Fluidigm Soared as Much as 58.6% Today
The struggling laboratory hardware developer received a $37 million infusion to tackle the coronavirus pandemic.
Coronavirus Vaccine Stocks: Investors Cannot Overlook These Risks
If coronavirus vaccine development efforts are a race, then pharmaceutical companies will need to hurdle more than clinical trials to be successful.
Here's Why MediciNova Is Soaring Today
The small-cap pharmaceutical company announced a collaboration to develop a coronavirus vaccine.
Here's Why Amyris Stock Rose as Much as 12.2% Today
The synthetic biology pioneer announced a collaboration for its vaccine adjuvant ambitions.
Missing in the Hydrogen Economy Pitch: The Tax Credit Cliff for Fuel Cells
Fuel-cell manufacturers have fixed the eyes of investors on the growth potential of a hydrogen economy, but it might be distracting from a looming financial crunch.
Twist Bioscience Has Gained 186% in 2020. Is the Synbio Stock a Buy?
The company's $2.7 billion valuation is being driven by the coronavirus pandemic and federal stimulus. It doesn't appear sustainable.
U.S. Uranium Output Hit an All-Time Low in 2019. Does It Matter?
Nuclear power plants provide roughly 20% of the nation's electricity, but domestic uranium production could have met just 0.4% of fuel requirements last year.
2 Stocks to Hold for the Next 20 Years
Two decades is a long time, but these up-and-coming biopharma companies could earn significantly larger valuations in that span.
Fuel Cell Investors Shouldn't Get Too Caught Up in the Hydrogen Economy Just Yet
Dreams of a hydrogen future have sent fuel cell stocks soaring in 2020, but investors might get burned by the technological hype.
Renewable Energy Is the New Growth Driver for Dominion Energy
The unexpected sale of its gas transmission and storage business makes regulated utility operations, and renewable energy, more important than ever.
Is Neoleukin Therapeutics a Buy?
The drug developer has an intriguing technology platform and expects to enter clinical trials before the end of 2020, but there are a few things investors cannot overlook.